RNS Number:3841L
Arana Therapeutics Limited
09 January 2008


For Immediate Release                                       9 January 2007


                           Arana Therapeutics Limited


Arana announces final receipt of $17.7 million from sale of Domantis Limited



Arana Therapeutics Limited, (AIM: AAHx ASX: AAH) (the "Company"), the Australian
biopharmaceutical company that uses superior technology to develop next
generation drugs that will improve the lives of patients with inflammatory
diseases and cancer has today announced that it had received the remaining funds
of A$17.7 million arising from the sale of its shareholding in Domantis Ltd in
January 2007.

CEO Dr John Chiplin commented "This is the final part of the very successful
sale of Domantis to GlaxoSmithKline. Arana's already strong financial position
has been made even stronger by the receipt of these funds. In these times of
uncertainty in financial markets, we are in a strong position arising from good
financial management."


"Our financial position is even better than it might have been, as we entered
into foreign exchange contracts with a net exchange rate of 0.40; significantly
more favourable to today's spot rates." Dr Chiplin added.



About Arana Therapeutics:


Arana Therapeutics (ASX: AAH; AIM: AAHx) is an international biopharmaceutical
company formed through the merger of Peptech and EvoGenix in August 2007. The
company uses superior technology to develop next generation drugs that will
improve the lives of patients with inflammatory diseases and cancer.


Arana Therapeutics' innovative engineering technologies provide the basis for
clinical development in the antibody space, a market which draws on high demand.
With a market capitalisation of around A$250 million and solid cash resources,
Arana Therapeutics has the financial stability and management expertise to
accelerate its clinical programs, and is on track to have at least 3 clinical
stage assets within three years.


Arana is listed on the Australian Securities Exchange (ASX) and the London Stock
Exchange (AIM).


The pipeline consists of four lead drug programs: ART621 to treat severe
rheumatoid arthritis and other inflammatory diseases; ART010 to treat
osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal
cancer; and ART150 for lung cancer and melanoma. Additionally, the company has
earlier stage products in development for the treatment of a range of conditions
including age related macular degeneration, psoriasis, colorectal cancer, and
leukaemia.


Arana has recurring revenues from commercial and development partnerships with
six international companies including GSK, CSL, Centocor (J&J) and Abbott
Laboratories.



For further information: www.arana.com


For further information, please contact:

Arana Therapeutics Limited
Dr John Chiplin, Chief Executive Officer             +61 (0)2 8061 9900
Niall Henderson, Chief Financial Officer             +61 (0)2 8061 9900

Buchanan Communication
Lisa Baderoon/Rebecca Skye Dietrich                 +44 (0)20 7466 5000

Nomura Code Securities
Charles Walker                                      +44 (0)20 7776 1200












                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
DISUUUQPGUPRUBB
Arana Therap. (LSE:AAHX)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Arana Therap. Charts.
Arana Therap. (LSE:AAHX)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Arana Therap. Charts.